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SUMMARY
Neisseria meningitidis is the main cause of bacterial meningitis and sepsis in the UK, and can
potentially be lethal or cause long-term sequelae. Bexsero® (4CMenB) is a new multi-component
vaccine approved by the European Commission for use in individuals aged 52 months.
A theoretical transmission model was constructed to assess the long-term effectiveness of
Bexsero compared to standard care. The model was populated with UK-speciﬁc demographic
data and calibrated to ensure that the transmission dynamics of meningococcal disease in the
UK were adequately simulated. The model showed the best strategy to be a routine vaccination
programme at ages 2, 3, 4, 12 months and 14 years combined with a 5-year catch-up programme
in toddlers aged 12–24 months and adolescents aged 15–18 years. This would lead to a 94%
reduction in meningococcal cases or 150000 cases and 15000 deaths over a 100-year time-frame.
Key words: Adolescents, Bexsero®, dynamic modelling, infants, meningococcal disease.
INTRODUCTION
Since the introduction of Haemophilus inﬂuenza type
B (Hib) and pneumococcal conjugate vaccines,
Neisseria meningitidis has become the leading cause
of bacterial meningitis and sepsis in the UK and
other countries. N. meningitidis can affect otherwise
healthy people of all ages; when it occurs, the disease
progresses rapidly, even with appropriate medical in-
tervention, and can lead to death within 24–48 h of
the ﬁrst symptoms [1]. Furthermore, 10–20% of survi-
vors have serious long-term complications such as
deafness, limb amputation or neurological deﬁcits [2].
Of the 13 serogroups identiﬁed, serogroups A, B, C,
W-135, X and Y are responsible for nearly all menin-
gococcal disease worldwide [3, 4]. The incidence of
N. meningitidis disease is highest in children aged
<2 years and shows a secondary peak in adolescents
and young adults in many geographical regions [5].
In contrast, the number of meningococcal carriers is
highest in young adults [6].
Before the introduction of a serogroup C meningo-
coccal (MenC) conjugate vaccine in the UK, about
2400 cases of meningitis were reported annually, pre-
dominantly due to serogroups B and C [7]. In 1999,
a MenC vaccination campaign was implemented
with catch-up initially targeting all children and ado-
lescents aged from 2 months to 18 years and subse-
quently extended to individuals up to 24 years of
age. As a result, during the ﬁrst 2 years of the UK
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MenC conjugate immunization programme, the at-
tack rate for invasive meningococcal serogroup C dis-
ease in the unvaccinated population was reduced by
67% [8]. Serogroup C disease rates declined markedly
in both immunized and non-immunized individuals,
presumably as a result of reductions in carriage and
subsequent ‘herd’ protection. The success of the UK
MenC programme led to similar introductions in
other countries, e.g. Ireland, The Netherlands,
Spain, and Australia [9, 10].
In countries where vaccination programmes com-
prised a large catch-up campaign, such as the UK
and The Netherlands, the decline in disease incidence
was more immediate than in those countries without
such programmes [11, 12].
Following the introduction of MenC, meningococ-
cal serogroup B (MenB) has emerged as the most
prevalent serogroup in Europe [13]. In the UK, 84%
of meningococcal infections are caused by serogroup
B, with an average of 1400 cases annually over the
decade from 2001 to 2010 [7].
No meningococcal vaccine is currently indicated
for prevention of MenB infections; however, a new
multi-component vaccine – Bexsero® (Novartis,
Switzerland) –was approved by the European Com-
mission in January 2013 for use in the European
Union in individuals aged 52 months. Bexsero has
four components: outer membrane vesicles (OMVs)
from the New Zealand MenB outbreak strain; fac-
tor H binding protein; neisserial adhesin A; and
Neisseria heparin-binding antigen. In clinical studies,
Bexsero has generated protective MenB antibody
levels, with acceptable tolerability in subjects as
young as 2 months [14] and protective antibody levels
against meningococci-expressing capsular groups
other than B (mainly serogroups A, C, W-135, X, Y)
[15, 16].
The objective of this analysis was to quantify the
potential beneﬁts of a Bexsero vaccination programme
in the UK for the prevention of meningococcal dis-
ease associated with serogroup B and potential
beneﬁts vs. serogroups W-135, and Y. Serogroups
A and X were not considered in this analysis owing
to the current low number of cases in the UK. A trans-
mission model that considers both the direct effects
of vaccination and the impact of herd immunity was
used to recommend a vaccination schedule that
would lead to (1) a rapid reduction in the overall num-
ber of vaccine-preventable (VP) meningococcal cases,
and (2) long-term elimination of VP meningococcal
disease.
METHODS
The model
This dynamic transmission model was based on a pub-
lished model of meningococcal serogroup C disease
transmission [17] and adapted to describe the trans-
mission of Bexsero-preventable meningococcal dis-
ease. In addition, using recently published carriage
data, the model was adapted to include the use of
UK-speciﬁc population contact matrices for calculat-
ing disease transmission and UK population esti-
mates, birth projections and mortality data rather
than a uniform population distribution. The model
was been programmed using Microsoft Excel 2010
(Microsoft, USA).
The model is dynamic in that the force of infection
changes over time based on rates of carriage within
the population; further, the rates of carriage change
with the force of infection. Using this model structure,
it was possible to estimate indirect beneﬁts of the vac-
cine on the vaccinated and unvaccinated population
by simulating the vaccine’s impact on carriage acqui-
sition. If a vaccine demonstrates an impact on carriage
acquisition, the overall number of subjects carrying
the bacteria is reduced within a population, in turn, re-
ducing the risk of infection for susceptible subjects
and leading to herd protection.
Structure
The transmission model comprised a set of nine mutu-
ally exclusive compartments deﬁned in terms of VP
(M) or non-VP (O) meningococcal carriage and vacci-
nation status (Fig. 1). At the starting point, subjects
are distributed across compartments based on
assumptions regarding the current prevalence of vacci-
nation, infection and disease. The ﬁrst column of
Figure 1 represents seroprotected subjects, the second
non-seroprotected subjects, and the third those with
meningococcal disease. The top row represents sub-
jects infected with VP meningococcal strains, the se-
cond row represents uninfected subjects who are
susceptible to infection, and the third row represents
subjects infected with non-VP meningococcal strains,
for whom it is assumed that co-infection with VP
meningococcal disease cannot occur.
Vaccination
During each model cycle of ∼7 hours (100 per 30
days), a proportion of subjects who reach predeﬁned
ages is vaccinated; subjects successfully vaccinated
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move from the state ‘susceptible’ (S) to ‘susceptible
seroprotected’ (SR) or from ‘infected’ to ‘infected sero-
protected’ (O to OR or M to MR, depending on
whether the meningococcal strain is VP). To account
for <100% vaccine efﬁcacy, the proportion of subjects
transitioning from the non-vaccinated to vaccinated
state is efﬁcacy-adjusted so that all subjects in the vac-
cinated state are both vaccinated and protected from
disease.
Vaccine impact
An assumption of the model is that successful vacci-
nation (seroconversion) confers complete protection
against VP meningococcal disease (direct effect) and
may confer some protection against VP carriage ac-
quisition (indirect effect). Only those subjects carry-
ing VP strains (i.e. ‘M’ compartment) are at risk of
VP meningococcal disease, while carriers of non-VP
strains (‘O’ compartment) are at risk of non-VP disease.
Importantly, the model does not allow for direct
transitions from carriage with VP meningococci to
carriage with non-VP meningococci, or vice versa.
As with previously published MenC vaccination mod-
els [18], it is assumed that co-infection with non-VP
and VP meningococci does not occur; therefore,
carriers of N. meningitidis of a VP strain are protected
from infection with non-VP strains. Moreover, con-
sistent with MenC models [18], transmission was
dynamically modelled only in VP meningococci, and
force of infection was assumed constant for non-VP
meningococci.
No vaccine cross-protection for non-VP meningo-
coccal strains was assumed, so successfully vaccinated
individuals acquired infection with non-VP meningo-
cocci at the same rate as non-vaccine protected
individuals.
Infection
During each model cycle, susceptible subjects (SR, S)
may become infected and acquire carriage of a VP
meningococcal strain (M) or a non-VP meningococcal
strain (O); they then transition to the infected
compartment corresponding to their infection and
vaccination status. Most carriers of VP or non-VP
meningococci recover without developing invasive
meningococcal disease (IMD) and, in time, return to
the susceptible state. A small proportion develop VP
disease (‘M’ to ‘MD’) or non-VP disease (‘O’ or
‘OR’ to ‘OD’). Subjects who recover from meningo-
coccal disease return to the non-vaccinated susceptible
state.
The detailed differential model equations are avail-
able in the Supplementary online material.
Ageing
All model compartments are repeated for each 1-year
age stratum; thus, for each health state there are 100
compartments (ages 0–99 years). At yearly intervals,
all surviving subjects move to the next age stratum.
A maximum life expectancy of 100 years was assumed
so all subjects not dying before this age (of meningo-
coccal disease or other conditions) exit the model at
Vaccinated with
resulting
seroprotection
Vaccine-preventable
strain carriers MRi Mi MDi
MDeathi
ODi
SRi Si
OiORi
Susceptibles
Other strain
carriers
Disease
Non-vaccinated or vaccinated
without seroprotection
due to <100% efficacy
Fig. 1 [colour online]. Meningococcal transmission model. M, Infected (vaccine preventable); MR, infected seroprotected
(vaccine preventable); OR, infected seroprotected (non-vaccine preventable); O, infected (non-vaccine preventable);
S, susceptible; SR, susceptible seroprotected; i, age stratum.
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the end of their 99th year. Each year, a new birth co-
hort of subjects aged 0 years is introduced into the
‘non-vaccinated susceptible’ (S) compartment.
Model parameters
Model population
The model was populated with UK-speciﬁc historical
and projected demographic data (2010 data) [13, 19,
20]. The age distribution of the UK population is in-
corporated into the model in 1-year age groups. The
population is assumed to change each year due to age-
ing, births and deaths. As birth projections were only
available until 2033, births were assumed constant
thereafter.
Epidemiology/number of VP cases
Meningococcal cases. Data for 2001–2010 from
governmental sources for England and Wales [21,
22], Scotland (A. Smith-Palmer, written communi-
cation April 2011) and Northern Ireland [23] were
used to determine the age-stratiﬁed average annual
number of meningococcal cases. Lacking data for
Northern Ireland, the age distribution of serogroup
B and C cases for 2001–2006 was assumed to match
that of 2007–2010. The age distribution of serogroup
W-135 and other cases was assumed to match the 2007–
2010 age distribution of all laboratory-conﬁrmed
cases. Cases deﬁned as ‘other’ or ‘non-groupable’
were redistributed by serogroup based on the distri-
bution of groupable cases. To reﬂect the reduced
number of cases since the MenC vaccination began,
only data from 2006 to 2010 were averaged for sero-
group C.
As evidence suggests that the ofﬁcially reported num-
bers underestimate the true burden of disease [24, 25],
calculation of cases for the base-case scenario used
Health Protection Agency (HPA) data (for IMD) cor-
rected to align with hospital admissions data (hospital
episode statistics; HES) for meningococcal meningitis,
meningococcaemia and other meningococcal infec-
tions. This correction factor for underreporting for
England was calculated as the percentage difference
between cases reported to the HPA for England and
Wales compared to population weighted cases re-
ported to the HES for England only from 2000/2001
to 2010/2011 [26]. For Northern Ireland, the factor
was calculated as the percentage difference in the
total (conﬁrmed and probable) and conﬁrmed cases
reported to the Public Health Agency for Northern
Ireland from 2000 to 2010; no correction has been ap-
plied for Scotland.
VP meningococcal cases. These are deﬁned as cases
of serotypes B, C, W-135 and Y disease for which
Bexsero provides effective coverage. This is consistent
with the methods used for evaluating the MenC vac-
cine when introduced into the UK vaccination pro-
gramme in 1999. The mathematical models used to
evaluate conjugated MenC vaccines, proven to elicit
bactericidal antibodies leading to killing of serogroup
C meningococci in vitro, considered only ‘relevant’
meningococcal cases, i.e. those cases caused by menin-
gococci effectively targeted by a MenC vaccine. Cases
caused by meningococci of other serogroups could not
be affected by the new MenC vaccines and therefore
were not considered in those evaluations.
Preliminary evidence suggests that Bexsero has the
potential to kill meningococci of multiple serogroups
due to the vaccine antigens shared across serogroups
[15, 16]. To estimate the coverage potential of
Bexsero against circulating meningococcal strains, a
meningococcal antigen-typing system (MATS) was
developed. This method is based on (and therefore
correlates with) killing of strains in the serum bacteri-
cidal assay using human complement (hSBA) from
pooled infant sera.
Based on MATS strain coverage, an estimated 73%
of serogroup B cases, 79% of serogroup C cases, 82%
of serogroupW-135 cases and 21% of serogroup Y cases
are expected to be VP [27]. Consistent with the meth-
ods used for evaluation of MenC vaccines, only those
‘relevant’ cases were considered in the present evalu-
ation. A correlation was established between MATS
relative potency and killing of serogroup B strains in
the hSBA by pooled immune serum from people
who have been vaccinated [27]; however, the corre-
lation of MATS and hSBA has not been established
for other N. meningitidis serogroups. Consequently,
the MATS estimation of coverage in non-serogroup
B (serogroups C, W-135, Y) is based on bactericidal
thresholds derived from relating MATS relative
potency levels to killing of serogroup B strains by in-
fant serum pools.
Model calibration
The model was calibrated to ensure that it accu-
rately simulates the incidence of meningococcal car-
riage and disease in the UK population. A published
WAIFW (who acquires infection from whom) matrix
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(table S8.4. b in [28]) was used to compute trans-
mission rates from the age-stratiﬁed force-of-infection
data.
The age-speciﬁc distribution of meningococcal car-
riage was obtained from a meta-analysis of carriage
estimates in multiple countries [6]. As carriage values
have been published for 0–74 years only, values were
carried forward to 75–99 years assuming the same de-
cline (0·1% per year) as reported for years 572. The
meta-analysis reported overall carriage only; there-
fore, it was assumed that the distribution of VP car-
riage in each age group mirrors the distribution of
VP cases.
Distribution of case-fatality rates across age groups
was obtained from [29]; adjustment factors can be ap-
plied to modify the absolute case fatalities depending
on the modelled scenario.
Similar to previously published methods [30], the
model was calibrated in three steps: (1) the age-speciﬁc
force of infection (λ) was calibrated for the starting
population and the age-speciﬁc carriage target values;
(2) the probabilities of effective contact (β) were solved
for each susceptible and carrier age group combi-
nation; and (3) the age-speciﬁc risk of disease given
carriage (θ) was calibrated to UK cases reported
over the last 10 years [21]. The same methods and pre-
deﬁned classes of functions as reported in the appen-
dix of [30] have been used to model the force of
infection as well as the risk of disease given infection.
Maximum-likelihood methods have then been applied
to ﬁt the force-of-infection parameters and the risk of
disease given infection parameters to the carriage and
disease data.
Time-frame
In the base-case analysis, meningococcal transmission
and outcomes (cases) were tracked over a 5-year and a
100-year time-frame.
Model inputs
The movement between compartments in the model
(Fig. 1) is dependent on the values of the input para-
meters and the model equations. The base-case par-
ameter values with corresponding data sources are
shown in Table 1. Rates of movement between com-
partments are assumed to follow an exponential distri-
bution in which a constant rate is applied to the
population in the relevant compartment.
Vaccination strategies evaluated
Mathematical modelling allows optimization of the
age at which vaccination strategies are implemented,
as well as targeting the catch-up programme to the
age cohorts yielding the most value. Four basic vacci-
nation strategies consistent with the product label
have been evaluated. In order to assess the impact of
catch-up programmes on the case reduction within
the ﬁrst years after implementation of a vaccine pro-
gramme, the early infant vaccination has been tested
in combination with a 5-year and a 17-year catch-up,
respectively. Finally, an adolescent component has
been added to the combination programmes in ad-
dition; all strategies evaluated are summarized in
Table 2. All vaccination programmes mentioned
were compared to the current UK standard of care
of two MenC doses at ages 3 and 4 months, and the
combined Hib and MenC conjugate vaccine given as
a booster between ages 12 and 13 months.
It is assumed that Bexsero will be added to the cur-
rent MenC vaccination programme and hence all ben-
eﬁts are assumed to be incremental to the current
vaccination schedule.
Uncertainty analysis
For the combination of routine vaccinations in early
infants and adolescents, together with a 5-year
catch-up programme (Table 2), a probabilistic sensi-
tivity analysis was performed with respect to the num-
ber of cases prevented vs. the current standard of care.
Parameters assessed included: likelihood of successful
vaccination; vaccine persistence (waning antibodies);
vaccine uptake; recovery from carriage; case fatality.
Narrow ranges were used when parameter value accu-
racy was well established (e.g. vaccination uptake);
wider ranges were used for parameters with less accu-
racy (e.g. waning rates) (Table 1). In addition, the
number of calibrated cases was varied between 0·62
and 1·68 of the base-case values, reﬂecting the range
of cases annually in the UK between 2001 and 2010,
with the age distribution of cases assumed to be the
same as in the base case. For the probabilistic sensi-
tivity analysis, estimates were drawn from a uniform
distribution for waning, recovery from carriage and
vaccination uptake parameters, while estimates for
all probabilities, including the probability of success-
ful vaccination vs. VP strains were drawn from a
beta distribution.
A random-number generator was used to ‘draw’
parameter values from each distribution. Next, the
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Table 1. Model input parameters
Parameter
Base case
value Distribution Data sources
Monthly rate of recovery from
vaccine-preventable carriage
0·11 Uniform (0·07–0·25) [18]
Proportion of vaccine-preventable
carriers who recover immediately after
vaccination
0·00 n.a. Assumption (no vaccine impact on
established carriage)
Vaccine impact on carriage acquisition 0·67 n.a. [31]
Case fatality by age [29]
<1 year 6·1% Beta (20; 308)
1–2 years 4·3% Beta (20; 445)
3–10 years 4·7% Beta (20; 406)
11–17 years 6·0% Beta (20; 313)
18–22 years 15·3% Beta (30; 165)
23–64 years 15·3% Beta (30; 165)
565 years 15·3% Beta (30; 165)
Probability of successful vaccination
vs. vaccine-preventable strains (starting
at 2 weeks post-vaccination)
Derived from Novartis Vaccine
Clinical data on ﬁle
Early infants
2 months 0·42 Beta (25; 34·5)
3 months 0·61 Beta (50; 32)
4 months 0·82 Beta (50; 11)
12 months 0·98 Beta (10; 0·2)
Late infants
6 months 0·61 Beta (50; 32)
8 months 0·82 Beta (50; 11)
12 months 0·98 Beta (10; 0·2)
Toddlers
12 months 0·90 Beta (30; 3·3)
14 months 0·98 Beta (10; 0·2)
Adolescents
14 years or age range deﬁned for
catch-up (two doses administered
51 month apart)
0·99 Beta (5; 0·05)
Monthly rate of waning vaccine
protection
Based on available clinical
persistence data and based on expert
opinion (similar to date with MenC
conjugate persistence data)
Infants (aged <1 year) 1/18 Uniform (1/9–1/27) Mean persistence of protection is
18 months, 36 months and
84 months, respectively
Toddlers (aged 1–3 years) 1/36 Uniform (1/19–1/54)
Children aged >3 years 1/84 Uniform (1/44–1/125)
Vaccination uptake Infants: average vaccination rates for
2006/2007, 2007/2008 and 2008/
2009 [32]
Infants 0·928 Uniform (0·925–0·94) Adolescents: assumed same uptake as
school-based HPV vaccination
programme [33]
Adolescents 0·85 Uniform (0·75–0·95)
HPV, Human papillomavirus; n.a., not applicable.
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model was re-calibrated using the drawn values for
carriage recovery rate and disease incidence. The
model was then run to generate estimates of the per-
centage reduction of VP cases. This process of draw-
ing and replacing parameters and then calibration
and running the model was repeated 1000 times.
Finally, the number of cases prevented standardized
to the case distribution associated with today’s stan-
dard of care was calculated for each model run; the
25th ranked and 975th ranked number of cases pre-
vented determined the upper and lower bounds of
the conﬁdence intervals (CIs).
RESULTS
Model calibration
Results of the calibration of the age-speciﬁc risk of VP
disease to the observed incidence of meningococcal
disease are presented in Figure 2. The fact that cases
of meningococcal disease are reported in 5-year
cohorts in the UK leads to a suboptimal model ﬁt
in teenagers and young adolescents. The risk of dis-
ease given carriage was highest in infants (1/200)
and declined steeply with age, reaching a plateau
(1/20000) in the population aged >40 years.
Model analysis
The estimated number of cases of meningococcal dis-
ease under the current standard of care (i.e. without
Bexsero vaccination) varies over time because of the
projected changes in the population structure. Under
the current standard of care, the model predicts 1640
cases of meningococcal disease in the ﬁrst year, 8048
within the ﬁrst 5 years (Table 3) and an annual
Table 2. Components of vaccination strategies assessed
Vaccination strategy Timing of administration of Bexsero
Basic routine vaccination programmes
A Early infant Ages 2, 3, 4, 12 months
B Late infant Ages 6, 8, 12 months
C Toddler Ages 12, 14 months
D Adolescent Two doses of Bexsero at 14 years (at least 1 month apart)
Combination programmes
E Early infant+5-year catch-up In addition to routine early infant vaccination, two doses have been administered in
year 1 to:
. 12- to 24-month-old toddlers
. 15- to 18-year-old adolescents
F Early infant+17-year catch-up In addition to routine early infant vaccination, two doses have been administered in
year 1 to:
. 2- to 18-year-old children and adolescents
G Early infant+adolescent+
5-year catch-up
In addition to routine early infant and routine adolescent vaccination, two doses
have been administered in year 1 to:
. 12- to 24-month-old toddlers
. 15- to 18-year-old adolescents
H Early infant+adolescent+
17-year catch-up
In addition to routine early infant and routine adolescent vaccination, two doses
have been administered in year 1 to:
. 2- to 18-year-old children and adolescents
500 Observed cases
Predicted cases
400
300
Nu
m
be
r o
f c
as
es
200
100
0 10 20 30 40 50
Age (years)
60 70 80 90 100
0
Fig. 2. Model calibration: observed and predicted cases of
vaccine-preventable disease by age.
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average of 1547 cases over the model’s 100-year time
horizon (Table 4). To allow for easier interpretation
given population changes over time, projected long-
term vaccination outcomes are reported relative to
the current standard of care.
First 5 years of vaccination programme
Model results conﬁrm that the early infant vaccination
strategy (Table 2) provides the best direct protection in
infants (Table 3). The early infant vaccination strategy
is estimated to prevent 2089 cases within the ﬁrst
5 years of the vaccination programme, including a
55% reduction in VP cases in infants aged <1 year
vs. the current standard of care. Under this strategy,
>50% of VP cases in infants aged 42 years are
averted, whereas <2% of VP cases in teenagers and
adults are averted through indirect protection
(Table 3). Overall, the number of preventable cases
is reduced by 26%.
In comparison with routine infant vaccination pro-
grammes, routine adolescent vaccination programmes
are characterized by a slow onset of protection from
meningococcal disease. In the ﬁrst 5 years of a vacci-
nation programme, routine adolescent vaccination
would prevent 655 cases of meningococcal disease
vs. the standard of care, i.e. 31% of the cases averted
with early infant vaccination.
Catch-up programmes
Short-term catch-up programmes in the ﬁrst year(s) of
the vaccination programme promote a faster re-
duction of VP cases. The larger the catch-up pro-
grammes, the faster and more complete the
protection from meningococcal disease (Table 3).
Compared with an early infant programme alone,
adding a 5-year/17-year catch-up prevents an ad-
ditional 1389/3253 cases, respectively, within the ﬁrst
5 years of the vaccination programme, leading to a
43%/66% reduction of VP cases in year 5 of the vacci-
nation programme vs. the current standard of care
(Table 3).
One-hundred-year model time horizon
Routine vaccination strategies in the ﬁrst 2 years of
life can lead to signiﬁcant reductions in VP cases with-
in 5 years of introduction of the vaccination pro-
gramme but reach a ‘plateau’ (steady state) about
40 years after the start of the programme (Fig. 3).
The addition of a catch-up component to such pro-
grammes accelerates reduction in cases; however, if
the catch-up programme does not lead to the eradi-
cation of VP disease, the long-term incidence level
will converge in the long-term to the same ‘plateau’
as the routine vaccination programme without a
catch-up component (Fig. 3).
Adding adolescent vaccination
Age at adolescent vaccination has been varied from 11
to 16 years, showing that vaccination programmes at
higher age lead to higher reduction of meningococcal
cases when assuming constant vaccination rates.
However, the differences between strategies were
small. In practice, however, it is assumed that high
rates of routine vaccination are more difﬁcult to
achieve in subjects aged515 years. If a routine infant
programme at ages 2, 3, 4 and 12 months together
with routine adolescent vaccination at 14 years is com-
bined with a 5-year catch-up programme, results sug-
gest that a 1-year catch-up in infants between 12 and
24 months should be administered, together with an
Table 3. Five-year cumulative number (per cent reduction compared to current standard of care) of
vaccine-preventable meningococcal cases, by vaccination strategy and age
Vaccination strategy
Age (years)
<1 1–2 3–10 11–17 18–22 523 All*
Current standard of care 2070 1457 1796 666 572 1487 8047
A Early infant 923 (55) 708 (51) 1656 (8) 656 (2) 564 (1) 1451 (2) 5958 (26)
B Late infant 1381 (33) 708 (51) 1667 (7) 658 (1) 566 (1) 1459 (2) 6437 (20)
C Toddler 2022 (2) 703 (52) 1673 (7) 660 (1) 568 (1) 1467 (1) 7094 (12)
D Adolescent 1961 (5) 1381 (5) 1691 (6) 448 (33) 516 (10) 1396 (6) 7392 (8)
E Early infant+5-year catch-up 791 (62) 443 (70) 1372 (24) 432 (35) 311 (46) 1221 (18) 4569 (43)
F Early infant+17-year catch-up 633 (69) 276 (81) 443 (75) 137 (79) 247 (57) 970 (35) 2705 (66)
* Numbers do not add up exactly due to rounding error.
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adolescent catch-up covering ages 15–18 years (strat-
egy G). In the ﬁrst 5 years, strategy G is estimated
to reduce the number of VP cases by 69% in children
aged 424 months, and by 48% in the overall popu-
lation. Over the ﬁrst 10 years of the vaccine pro-
gramme, 75% of cases aged <24 months and 59% of
expected cases would be prevented compared to the
standard of care. Over a 100-year time-frame, strategy
G would prevent 94% of cases (Table 4).
Impact on carriage acquisition
Indirect protection of the unvaccinated population
will occur only if the vaccine reduces carriage acqui-
sition. Assuming a 100-year time horizon, the vac-
cine’s impact on carriage acquisition and disease
prevention under strategy G is shown in Figure 4.
Assuming 555% vaccine efﬁcacy vs. carriage acqui-
sition, Bexsero will prevent 590% of VP cases; with
only an assumed 30% impact on carriage acquisition,
Strategy G nevertheless is estimated to prevent almost
70% of such cases. Assuming no vaccine impact on
carriage acquisition at all, Bexsero will prevent almost
40% of VP cases (Fig. 4).
Uncertainty analysis
Results from the probabilistic sensitivity analysis of
strategy G indicate that Bexsero is expected to prevent
93·5% (95% CI 84·9–96·5) of VP cases over 100 years.
Figure 5 shows the percentage reduction in VP menin-
gococcal disease cases over the modelled 100-year
time-frame relative to the standard of care, with theT
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2·5% and 97·5% percentiles from the probabilistic sen-
sitivity analysis.
DISCUSSION
We developed a mathematical model to compare
alternative vaccination programmes for the prevention
of meningococcal disease in the UK setting, using
similar methods and model structures as recently pub-
lished [34]. As recommended by international guide-
lines [35], we used a dynamic model to fully capture
the clinical value of a meningococcal vaccine. In
contrast, static models assume a ﬁxed force of infec-
tion and do not capture potential herd protection;
they may, therefore, greatly overestimate the remain-
ing cases of disease after the introduction of vacci-
nation and underestimate the potential beneﬁts of a
vaccination programme [13].
Results indicate that routine adolescent vaccination
alone cannot achieve the high protection levels within
the ﬁrst 5 years of a vaccination programme seen with
routine vaccination in early infants. This is explained
by the relatively low number of meningococcal cases
in adolescents and the associated low number of
cases prevented as a result of direct protection, com-
pared to infants. Moreover, the results conﬁrm that
the earlier infants are successfully vaccinated, the
better their protection against meningococcal disease.
Indeed, meningococcal disease can occur very early in
life with a considerable number of cases reported in
children aged <6 months. Vaccination programmes
in which the ﬁrst vaccine is given at 6 months or
later cannot prevent these early infections.
Overall, catch-up programmes promote faster and
greater reductions in meningococcal cases, but this
trend will converge in the long term to the same ‘pla-
teau’ as the respective routine vaccination programme
without a catch-up component. Our results suggest
that the elimination of VP cases requires a twofold ap-
proach: (1) a routine infant immunization programme
to provide direct protection to those at greatest risk;
(2) persistent reduction of the carriage reservoir, pri-
marily in adolescents and young adults, through
on-going vaccination. The reduction of preventable
cases through indirect protection provided by routine
adolescent vaccination can exceed that of direct pro-
tection and can lead to the elimination of VP menin-
gococcal disease, assuming a sufﬁciently high rate of
vaccination uptake. The results are sensitive to
assumptions about vaccine impact on carriage acqui-
sition. An OMV-based vaccine could be shown to re-
duce the likelihood of carriage by 85% during an
on-going MenB outbreak in the Normandy region
of France [36]; OMV is one of the four components
of Bexsero. Another study designed to assess pharyn-
geal carriage impact of the vaccine in a population
with known high pharyngeal carriage rates supports
the proof of concept that 4CMenB would provide
herd protection against meningococcal disease but
does not allow quantifying the reduction of individual
carriage acquisition [37]. However, an appropriate
translation of the individual carriage impact into an
estimate of herd protection can only be based upon
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results of further studies after the implementation
of large-scale vaccination programmes. Based on the
evidence and in lieu of any model to predict herd pro-
tection, the precedent from previous MenC vacci-
nation programmes [8] of 67% has been chosen for
4CMenB.
There are inherent limitations in disease modelling
and this was no different for our evaluation. In par-
ticular, there were limited data on relevant parameters
and assumptions were made about their likely value
and the variability that may exist around them.
Evidence-based data were used where available. For
example, we used clinical trial-derived likelihood of
successful vaccination, laboratory-evaluated strain
coverage and expected vaccine uptake, although
even for these values some uncertainty remains. As
with many new vaccines, long-term clinical data are
unavailable, e.g. vaccine persistence for Bexsero is
currently not fully assessed. In such cases, expert opi-
nion and previous experience were used to deﬁne ap-
propriate parameter values and any possible vari-
ability around these values.
The reasons for the unpredictable ‘natural ﬂuctua-
tion’ of cases of meningococcal disease over time,
the changes of serogroup distribution within a country
over time as well as the differences across geographies
are not yet fully understood. To reﬂect these phenom-
ena the average of reported numbers from 2001 to
2010 has been used for the base case (adjusting for
the decline in incidence due to MenC vaccination)
whereas the full range of reported numbers has been
considered in the sensitivity analyses. Since 2010, the
numbers have declined further. Efforts should be
taken to fully understand the underlying reasons for
the observed ﬂuctuation of IMD incidence.
We did not consider the seasonality of meningococ-
cal disease. Seasonality needs to be considered if the
intention is to estimate the expected reduction of VP
cases in the short term (over the ﬁrst few years) after
the start of the vaccination programme. The subopti-
mal model ﬁt between estimated and observed menin-
gococcal disease numbers, particularly in school-aged
children and teenagers (Fig. 2), is not considered as
a major limitation of this study. As mentioned, the
relative poor model ﬁt is explained by the fact that
reported disease cases are grouped into 5-year cohorts
– and the incidence numbers obtained from the ﬁtted
model are believed to reﬂect the reality better than the
grouped numbers reported. Fitting more complex
functions may require more parameters, which are be-
lieved to offset any potential gains from obtaining a
better model ﬁt. Further investigations in this area
may be needed.
Estimates of the proportion of circulating meningo-
coccal disease preventable by the vaccine can be
considered conservative, as the method used for
MATS does not include potential synergistic effects
between vaccine antigens and does not consider cover-
age from non-PorA P1·4 components (PorA P1·4
is the immunodominant protein antigen contained in
the OMV derived from MenB strain NZ98/254) of
the OMV. Moreover, vaccine coverage was estimated
based on post-vaccination sera collected from infants
aged 12 months; coverage is expected to be greater
in older age groups such as adolescents and adults.
We did not incorporate strain replacement into the
current model. Because Bexsero contains multiple
components and half of strains tested are covered by
more than one Bexsero antigen, it is likely to retain ef-
fectiveness if one antigen is down-regulated or
mutated. Thus, based on the characteristics of
Bexsero and epidemiological evidence from previous
vaccination programmes with serogroup-speciﬁc
meningococcal vaccines, we considered the theoretical
risk to be low for replacement by serogroups or
speciﬁc strains within a serogroup that were not tar-
geted by the vaccine.
Finally, our intention was to identify a Bexsero vac-
cination schedule that achieves both rapid reduction
of the overall number of VP meningococcal cases
and long-term elimination of VP meningococcal dis-
ease. Based upon our ﬁndings, such a programme
may comprise routine administration of Bexsero to
infants as early as possible, e.g. at ages 2, 3, 4 and
12 months, routine adolescent vaccination with two
doses of Bexsero administered at 14 years and an ado-
lescent catch-up programme in the ﬁrst year of the
vaccination programme. The catch-up programme
should at least cover vaccination of all toddlers be-
tween ages 12 and 24 months which, in the case of
Bexsero, would require two doses, as well as vacci-
nation of the four adolescent cohorts between ages
15 and 18 years, again with two doses of Bexsero. If
implemented in the UK, such a programme would po-
tentially prevent about 150000 cases and 15000
deaths over a 100-year period.
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